

Generalized Anxiety Disorder: A Comprehensive Review of Diagnostic Frameworks and Clinical Implications

Generalized Anxiety Disorder (GAD) is a pervasive and often debilitating mental health condition characterized by persistent and excessive worry. This report synthesizes the diagnostic criteria, clinical presentation, epidemiology, and etiological factors of GAD, drawing primarily from the *Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision* (DSM-5-TR)¹ and the *Clinical descriptions and diagnostic requirements for ICD-11 mental, behavioural and neurodevelopmental disorders* (ICD-11 CDDR).¹ The analysis aims to provide a comparative understanding of how these authoritative classification systems conceptualize GAD, highlighting their areas of convergence and divergence, and exploring the broader implications for clinical practice and research.

Diagnostic Frameworks and Classification

Nomenclatural and Coding Standards

Generalized Anxiety Disorder is consistently recognized across major international diagnostic systems. Under the *International Statistical Classification of Diseases and Related Health Problems, Tenth Revision* (ICD-10), GAD is coded as F41.1.¹ This same ICD-10 code, F41.1, is also utilized by the DSM-5-TR for GAD.¹ With the advent of the *International Classification of Diseases, Eleventh Revision* (ICD-11), GAD is assigned the code 6B00.¹

The consistent ICD-10 code across the DSM-5-TR and the ICD-11 CDDR, alongside the distinct ICD-11 code, underscores GAD's established status as a recognized diagnostic entity within global psychiatric classification systems. The preface to the DSM-5-TR explicitly notes efforts to align its classification structure with ICD-11, aiming to improve global health statistics, facilitate clinical trials, and enhance the replication of scientific findings across international boundaries.¹ However, it also acknowledges that complete harmonization of diagnostic criteria was not fully achieved due to differing developmental timelines for the respective manuals.¹ This scenario indicates a shared fundamental understanding of GAD as a

disorder but also highlights an ongoing, iterative process of refining diagnostic criteria. The subtle differences in criteria, despite shared codes, necessitate careful consideration in international research and clinical practice to ensure diagnostic consistency and comparability.

Diagnostic Criteria: A Comparative Analysis

Both the DSM-5-TR and ICD-11 CDDR provide detailed criteria for the diagnosis of GAD, with notable similarities and some distinctions in their approach.

DSM-5-TR Diagnostic Criteria (F41.1) ¹:

- **A. Excessive anxiety and worry (apprehensive expectation):** This must occur more days than not for at least 6 months, pertaining to a number of events or activities (e.g., work or school performance). The intensity, duration, or frequency of this anxiety and worry is considered disproportionate to the actual likelihood or impact of the anticipated event.
- **B. Difficulty controlling the worry:** The individual experiences significant difficulty in managing their worry and preventing worrisome thoughts from interfering with their attention to tasks at hand.
- **C. Associated symptoms:** The anxiety and worry are accompanied by three (or more) of the following six symptoms, with at least some symptoms present for more days than not for the past 6 months:
 1. Restlessness or feeling keyed up or on edge.
 2. Being easily fatigued.
 3. Difficulty concentrating or mind going blank.
 4. Irritability.
 5. Muscle tension.
 6. Sleep disturbance (difficulty falling or staying asleep, or restless, unsatisfying sleep).
 - A critical note: Only one of these six associated symptoms is required for diagnosis in children.
- **D. Clinically significant distress or impairment:** The anxiety, worry, or physical symptoms must cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.
- **E. Exclusion of physiological effects:** The disturbance must not be attributable to the physiological effects of a substance (e.g., a drug of abuse, a medication) or another medical condition (e.g., hyperthyroidism).
- **F. Exclusion of other mental disorders:** The disturbance is not better explained by another mental disorder. The DSM-5-TR provides specific examples for differentiation, such as anxiety or worry about having panic attacks in panic disorder, negative evaluation in social anxiety disorder, contamination or other obsessions in obsessive-compulsive disorder, separation from attachment figures in separation anxiety disorder, reminders of traumatic events in posttraumatic stress disorder, gaining

weight in anorexia nervosa, physical complaints in somatic symptom disorder, perceived appearance flaws in body dysmorphic disorder, having a serious illness in illness anxiety disorder, or the content of delusional beliefs in schizophrenia or delusional disorder.

ICD-11 Diagnostic Criteria (6B00) ¹:

- **Marked symptoms of anxiety:** These symptoms must persist for at least several months, occurring for more days than not. This marked anxiety is manifested in either:
 - General apprehensiveness that is not restricted to any particular environmental circumstance (i.e., "free-floating anxiety"); or
 - Excessive worry (apprehensive expectation) about negative events occurring in several different aspects of everyday life (e.g., work, finances, health, family).
- **Accompanied by additional characteristic symptoms:** These include: muscle tension or motor restlessness; sympathetic autonomic overactivity (evidenced by frequent gastrointestinal symptoms such as nausea and/or abdominal distress, heart palpitations, sweating, trembling, shaking and/or dry mouth); subjective experience of nervousness, restlessness or being "on edge"; difficulty concentrating; irritability; and sleep disturbances (difficulty falling or staying asleep, or restless, unsatisfying sleep).
- **Exclusion of other conditions:** The symptoms are not a manifestation of another health condition (e.g., hyperthyroidism), and are not due to the effects of a substance or medication on the central nervous system (e.g., caffeine, cocaine), including withdrawal effects (e.g., alcohol, benzodiazepines).
- **Functional impact:** The symptoms must result in significant distress about experiencing persistent anxiety symptoms or significant impairment in personal, family, social, educational, occupational, or other important areas of functioning. If functioning is maintained, it is only through significant additional effort.

Duration Required for Diagnosis

The duration requirement for GAD differs slightly between the two manuals. The DSM-5-TR specifies that excessive anxiety and worry must occur more days than not for **at least 6 months**.¹ In contrast, the ICD-11 requires symptoms to persist for **at least several months**, for more days than not.¹

This difference in duration criteria reflects a fundamental divergence in the philosophical underpinnings of these diagnostic systems. The DSM-5-TR's explicit "6 months" duration and precise "3 of 6 symptoms" criteria aim for higher diagnostic reliability and comparability in research. This approach prioritizes a more stringent, research-driven definition, emphasizing quantifiable thresholds. Conversely, ICD-11's use of "several months" and a less prescriptive symptom count aligns with its stated philosophy of avoiding "artificial precision" that could create barriers to care or limit applicability across diverse cultural contexts.¹ This flexibility in ICD-11 is designed to be more clinically useful in varied real-world settings, recognizing that rigid numerical thresholds might not always capture the full spectrum of presentations or be culturally appropriate. Consequently, a patient might meet GAD criteria in one system but not

the other, leading to implications for international research and clinical practice.

Exclusion Criteria / Rule-Outs

Both DSM-5-TR and ICD-11 place significant emphasis on ruling out alternative explanations for anxiety symptoms. Both manuals explicitly state that the disturbance should not be attributable to underlying medical conditions (e.g., hyperthyroidism) or substance/medication-induced effects (e.g., caffeine, cocaine, or withdrawal from alcohol or benzodiazepines).¹

Beyond physiological causes, both systems require that GAD symptoms are not better explained by another mental disorder. The DSM-5-TR provides a comprehensive list of specific mental disorders for differentiation, including Panic Disorder, Social Anxiety Disorder, Obsessive-Compulsive Disorder, Separation Anxiety Disorder, Posttraumatic Stress Disorder, and various somatic or psychotic disorders.¹ Similarly, the ICD-11 CDDR details differentiations from Panic Disorder, Social Anxiety Disorder, Depressive Disorders, Adjustment Disorder, Obsessive-Compulsive Disorder, Hypochondriasis (Health Anxiety Disorder), Bodily Distress Disorder, and Post-Traumatic Stress Disorder in its "Boundaries with other disorders and conditions" section.¹

The extensive lists of exclusion criteria and differential diagnoses in both manuals underscore that GAD is often a diagnosis of exclusion. This means that a thorough clinical evaluation, including a medical workup and careful consideration of other psychiatric conditions, is paramount. The detailed guidance on differentiating GAD from conditions with overlapping symptoms, such as panic attacks or depressive symptoms, is crucial. This approach highlights the inherent complexity of psychiatric diagnosis and the necessity for skilled clinical judgment to prevent misdiagnosis. It also implicitly suggests that GAD frequently presents within a complex clinical picture, demanding a broad understanding of psychopathology from the diagnosing clinician.

Specifiers / Subtypes

Neither the DSM-5-TR nor the ICD-11 CDDR delineate specific subtypes for Generalized Anxiety Disorder. However, both manuals include a general "with panic attacks" specifier that can be applied to GAD.¹ This specifier is utilized when panic attacks occur in the context of GAD but do not warrant a separate diagnosis of Panic Disorder, for instance, if the panic attacks are exclusively triggered by GAD-related worries.¹

The absence of formal subtypes for GAD in both major classification systems suggests that GAD is largely considered a unitary diagnostic construct. The presence of a "with panic attacks" specifier across various anxiety disorders indicates that while panic attacks can co-occur, they are viewed as an associated feature or a marker of severity rather than defining a distinct subtype of GAD. This approach streamlines diagnosis by avoiding overly

granular subcategories, while still allowing for the notation of clinically significant symptomatic variations like panic attacks, which can influence prognosis and treatment planning.

Severity Levels

Both the DSM-5-TR and ICD-11 state that the symptoms of GAD must cause "clinically significant distress or impairment in social, occupational, or other important areas of functioning" to meet diagnostic criteria.¹ However, neither document provides explicit mild, moderate, or severe specifiers specifically for GAD, unlike for Major Depressive Disorder in DSM-5-TR¹ or Depressive Episode severity in ICD-11.¹

The reliance on "clinically significant distress or impairment" as the threshold for diagnosis, rather than graded severity specifiers, suggests that for GAD, the primary indicator of severity is the degree of functional impact. This contrasts with disorders like depression, where symptom count and intensity can define specific severity levels. This implies that even if symptom intensity fluctuates, the presence of any significant impairment warrants diagnosis. Therefore, a clinical assessment of GAD severity would heavily rely on a thorough evaluation of the individual's daily functioning across various life domains.

Contrasts with Other Sources (Key Differences in Diagnostic Approaches)

Beyond the duration requirement, other key differences in the diagnostic approaches of DSM-5-TR and ICD-11 for GAD are apparent:

- **Symptom Quantification:** The DSM-5-TR mandates a specific count of associated symptoms, requiring "three (or more) of the following six symptoms".¹ In contrast, ICD-11 lists "additional characteristic symptoms" without a numerical threshold, allowing for greater clinical judgment in determining if the overall symptom picture meets the criteria.¹
- **"Free-Floating Anxiety":** ICD-11 explicitly includes "general apprehensiveness that is not restricted to any particular environmental circumstance (i.e. 'free-floating anxiety')" as a manifestation of marked anxiety.¹ While DSM-5-TR's description of "excessive anxiety and worry... about a number of events or activities" covers similar ground, the explicit mention of "free-floating" in ICD-11 maintains a historical conceptualization of GAD.

These variations in duration and symptom quantification between DSM-5-TR and ICD-11 reflect a fundamental philosophical divergence. The DSM-5-TR tends towards operationalized, quantifiable criteria to enhance research and inter-rater reliability. This approach is rooted in a desire for empirical precision and consistency across studies. Conversely, ICD-11, particularly its CDDR, prioritizes clinical utility and flexibility,

acknowledging cultural and contextual variations that might not fit rigid numerical rules.¹ The explicit inclusion of "free-floating anxiety" in ICD-11 further suggests a continuity with classical psychiatric thought, emphasizing the pervasive, non-situational nature of GAD. These differences mean that a patient might meet criteria for GAD in one system but not the other, or that the diagnostic process might feel more prescriptive in a DSM-5-TR-oriented setting versus a more clinically nuanced approach in an ICD-11-oriented one. This has significant implications for cross-cultural diagnosis, epidemiological studies, and the generalizability of research findings.

Table 1: Comparative Diagnostic Criteria for Generalized Anxiety Disorder (GAD)

Criterion/Feature	DSM-5-TR (F41.1)	ICD-11 (6B00)
Core Anxiety/Worry	Excessive anxiety and worry (apprehensive expectation) about a number of events or activities; intensity/duration/frequency disproportionate to actual likelihood/impact.	Marked symptoms of anxiety (general apprehensiveness or excessive worry about multiple everyday events).
Duration	Occurring more days than not for at least 6 months.	Persisting for at least several months, for more days than not.
Difficulty Controlling Worry	Individual finds it difficult to control the worry and keep worrisome thoughts from interfering with tasks.	Accompanying symptom: Subjective experience of nervousness, restlessness or being "on edge"; difficulty concentrating.
Associated Symptoms (Number/Examples)	Three (or more) of six symptoms (restlessness, easily fatigued, difficulty concentrating, irritability, muscle tension, sleep disturbance). One symptom for children.	Additional characteristic symptoms such as: muscle tension/motor restlessness, sympathetic autonomic overactivity, subjective nervousness/restlessness, difficulty concentrating, irritability, sleep disturbances. (No specific number required).
Distress/Impairment	Causes clinically significant distress or impairment in social, occupational, or other important areas of functioning.	Results in significant distress or significant impairment in personal, family, social, educational, occupational, or other important areas of functioning. If functioning maintained, only through

		significant additional effort.
Exclusion: Medical/Substance	Not attributable to physiological effects of a substance or another medical condition.	Not a manifestation of another health condition and not due to effects of a substance or medication.
Exclusion: Other Mental Disorders	Not better explained by another mental disorder (e.g., panic disorder, social anxiety disorder, OCD, PTSD, depressive disorders, somatic symptom disorder, body dysmorphic disorder, illness anxiety disorder, schizophrenia, delusional disorder).	Not better accounted for by another mental disorder (implicit in "Boundaries with other disorders" section, e.g., depressive disorder, adjustment disorder, OCD, hypochondriasis, PTSD).

Clinical Presentation and Symptomatology

Core Symptoms

The central feature of GAD in both classification systems is excessive anxiety and worry. The DSM-5-TR describes this as "excessive anxiety and worry (apprehensive expectation), occurring more days than not for at least 6 months, about a number of events or activities".¹ The individual finds it difficult to control this worry. Similarly, ICD-11 characterizes GAD by "marked symptoms of anxiety that persist for at least several months, for more days than not," manifested as either "general apprehensiveness that is not restricted to any particular environmental circumstance (i.e. 'free-floating anxiety')" or "excessive worry (apprehensive expectation) about negative events occurring in several different aspects of everyday life".¹ Both definitions converge on "excessive worry" as the central feature of GAD. The explicit mention of "free-floating anxiety" in ICD-11 emphasizes the pervasive, non-situational nature of GAD, distinguishing it from phobias or panic disorder where anxiety is typically tied to specific triggers. This highlights that the core of GAD is not merely *what* one worries about, but the *uncontrollable and generalized nature* of the worry itself. This distinction is crucial for differential diagnosis and for guiding therapeutic interventions that address the underlying cognitive processes of generalized worry, rather than solely focusing on specific feared situations.

Cognitive Features

Individuals with GAD exhibit distinct cognitive patterns. The DSM-5-TR notes "apprehensive expectation" and "difficulty concentrating or mind going blank".¹ Adults with GAD commonly worry about everyday, routine life circumstances, such as job responsibilities, health, finances, and the well-being of family members, or even minor matters. In children, excessive worry often centers on their competence or the quality of their performance. The focus of worry may shift over time during the course of the disorder.¹ ICD-11 similarly identifies "excessive worry (apprehensive expectation)" and "difficulty maintaining concentration" as key cognitive symptoms.¹ It further elaborates that the content of worry varies by age, with children and adolescents tending to worry about academic and sports performance, while adults worry more about their own well-being or that of their loved ones.¹

The consistent mention of "difficulty concentrating" and "excessive worry" in both manuals reinforces the significant cognitive burden imposed by GAD. The age-specific worry content is a significant developmental consideration: while the *process* of worrying remains stable, the *themes* of worry adapt to the individual's developmental stage and salient life concerns. This underscores the need for age-appropriate assessment tools and therapeutic approaches that address the specific content of worry relevant to the individual's life stage. For example, interventions for children might focus on academic perfectionism, whereas those for older adults might address concerns about health and safety.

Emotional Symptoms

Emotional manifestations of GAD include a persistent state of heightened arousal and negative affect. The DSM-5-TR lists "restlessness or feeling keyed up or on edge" and "irritability" as associated symptoms, noting that individuals report subjective distress from constant worry.¹ ICD-11 similarly includes "subjective experience of nervousness, restlessness or being 'on edge'" and "irritability" among its characteristic symptoms.¹

The shared emphasis on restlessness, feeling "on edge," and irritability as core emotional symptoms is noteworthy. Irritability, in particular, can be a less obvious manifestation of anxiety and may be misattributed or overlooked, especially in children where it can be pervasive.¹ Recognizing irritability as a prominent emotional symptom of GAD is crucial for clinicians, as it can significantly impact interpersonal relationships and may be a key target for therapeutic intervention. Its presence can also assist in differentiating GAD from other conditions where irritability may be less central.

Behavioral Symptoms

Behavioral manifestations of GAD often reflect attempts to cope with or avoid the distress of chronic worry. The DSM-5-TR implicitly points to avoidance behaviors through its discussion of functional impairment. It also notes an "exaggerated startle response" and describes

children with GAD as potentially "overly conforming, perfectionistic, unsure of themselves," tending to "redo tasks because of excessive dissatisfaction with less-than-perfect performance," and being "overzealous in seeking reassurance and approval".¹ ICD-11 explicitly lists "muscle tension or motor restlessness" and behavioral changes such as "avoidance, frequent need for reassurance (especially in children) and procrastination".¹ It clarifies that these behaviors typically represent an effort to reduce apprehension or prevent untoward events from occurring. In children, additional behaviors may include becoming upset when peers act out, excessively reporting on peers' misbehavior, or acting as an authority figure around peers, which can negatively affect interpersonal relationships.¹

Both manuals highlight avoidance and reassurance-seeking as prominent behavioral manifestations. ICD-11 provides a deeper understanding by explicitly stating that these behaviors are *efforts to reduce apprehension or prevent negative events*. This reframes them not merely as symptoms, but as maladaptive coping strategies. The detailed description of child-specific behaviors, such as over-conforming, perfectionism, and excessive reassurance-seeking, is particularly valuable. Understanding these behaviors as attempts to manage anxiety is critical for therapeutic intervention, as effective treatment often involves replacing these maladaptive strategies with healthier ones. The developmental variations underscore the need for age-sensitive behavioral observations and interventions.

Somatic/Physical Symptoms

The physical toll of chronic anxiety is evident in the somatic symptoms associated with GAD. Both manuals list muscle tension (which can manifest as trembling, twitching, feeling shaky, and muscle aches or soreness), easy fatigability, and sleep disturbance (difficulty falling or staying asleep, or restless, unsatisfying sleep).¹ The DSM-5-TR adds that many individuals also experience somatic symptoms like sweating, nausea, and diarrhea, along with an exaggerated startle response.¹ It specifies that symptoms of autonomic hyperarousal (e.g., accelerated heart rate, shortness of breath, dizziness) are less prominent in GAD than in other anxiety disorders, such as panic disorder.¹ ICD-11 refers to "sympathetic autonomic overactivity" evidenced by frequent gastrointestinal symptoms (nausea, abdominal distress), heart palpitations, sweating, trembling, shaking, and dry mouth.¹ In children, common somatic symptoms include frequent headaches, abdominal pain, and gastrointestinal distress.¹ Both manuals note the frequent co-occurrence of GAD with stress-related conditions like irritable bowel syndrome and headaches.¹

The extensive list of somatic symptoms in both manuals underscores the significant physical manifestation of GAD. The observation that autonomic hyperarousal is *less prominent* than in panic disorder is a key differential diagnostic point, guiding clinicians away from panic disorder if somatic symptoms are more chronic and diffuse rather than acute and episodic. The frequent co-occurrence with stress-related medical conditions further highlights the physiological impact of chronic anxiety. Clinicians, especially in primary care settings, must be vigilant in recognizing these physical complaints as potential indicators of GAD, rather than

solely focusing on organic causes. This is particularly relevant in cultures where somatic complaints may predominate over cognitive expressions of distress.

Insight / Awareness of Illness

Neither the DSM-5-TR nor the ICD-11 CDDR provide a specific section or explicit criteria regarding insight or awareness of illness for GAD.¹ However, for other disorders like Obsessive-Compulsive Disorder and Body Dysmorphic Disorder, ICD-11 includes specifiers for "fair to good insight" and "poor to absent insight".¹

The absence of explicit insight specifiers for GAD, unlike for conditions where insight is a variable and diagnostically significant feature, implies that individuals with GAD are generally presumed to have intact awareness into the excessive or irrational nature of their worries. While they may struggle to control the worry, they typically recognize it as problematic. This distinction helps differentiate GAD from disorders involving psychotic features or severe body dysmorphic disorder, where a lack of awareness into the delusional nature of beliefs is central. For GAD, the challenge lies in managing the *experience* of anxiety and worry, not in recognizing its pathology.

Cultural Considerations in Presentation

Cultural factors significantly influence the presentation and interpretation of GAD symptoms. The DSM-5-TR notes considerable cultural variation in the expression of GAD, with somatic symptoms predominating in some contexts and cognitive symptoms in others. This difference may be more evident during initial presentation. The content of worry can also be culturally specific, and it is important to consider the social and cultural context when evaluating whether worries are excessive.¹

ICD-11 elaborates on these points, stating that for many cultural groups, somatic complaints rather than excessive worry may predominate in the clinical presentation, sometimes involving physical complaints not typically associated with GAD, such as dizziness and heat in the head.¹ In some cultural contexts, symptoms of fear and anxiety may be described primarily in terms of external forces or factors (e.g., witchcraft, sorcery, malign magic or envy), rather than as an internal experience or psychological state.¹ Realistic worries may be misjudged as excessive without appropriate contextual information, such as migrant workers legitimately worrying about deportation threats from their employer.¹ Worry content may also vary by cultural group, relating to salient topics in the milieu, such as the spiritual status of deceased relatives in the afterlife in some societies, or personal achievement in more individualistic cultures.¹

Both manuals strongly emphasize the cultural shaping of GAD presentation, particularly the predominance of somatic symptoms and external attributions. These are not merely variations in expression but can fundamentally alter how distress is conceptualized and communicated.

This necessitates a culturally informed diagnostic approach, where clinicians actively explore the patient's explanatory models of illness, consider culturally normative expressions of distress, and contextualize worries within the individual's socio-cultural environment. Failure to do so risks misdiagnosis, underdiagnosis, or inappropriate treatment, particularly for individuals from non-Western or marginalized backgrounds.

Epidemiology and Course

Age of Onset

The typical age of onset for GAD tends to be later than for other anxiety disorders. The DSM-5-TR reports a mean age of onset of 35 years in North America, noting that the disorder rarely occurs prior to adolescence.¹ However, the age of onset is spread over a very broad range and tends to be older in lower-income countries worldwide.¹ ICD-11 states that onset may occur at any age, but the typical age is during the early to mid-30s. It also highlights that earlier symptom onset is associated with greater functional impairment and the presence of co-occurring mental disorders.¹

GAD's relatively later mean age of onset compared to other anxiety disorders is a notable epidemiological pattern. The consistent finding in both manuals that earlier onset is associated with greater impairment and comorbidity suggests that the disorder, when manifesting earlier in life, may be more pervasive or entrenched. This could potentially disrupt developmental milestones and increase vulnerability to other conditions. This highlights the importance of early identification and intervention, particularly in younger populations, to potentially mitigate long-term impairment and comorbidity. It also suggests that GAD presenting in early adulthood or adolescence may represent a more severe or complex phenotype.

Gender Prevalence

There is a consistent gender disparity in the prevalence of GAD. The DSM-5-TR indicates that women and adolescent girls are at least twice as likely as men and adolescent boys to experience GAD. In clinical settings, women constitute approximately 55%–60% of individuals presenting with the disorder, while in epidemiological studies, this figure rises to about two-thirds.¹ ICD-11 similarly states that the lifetime prevalence of GAD is approximately twice as high among women. It further notes that among individuals with onset during childhood or adolescence, girls are likely to have earlier symptom onset.¹

The consistent finding across both manuals of a significantly higher prevalence of GAD in women (approximately a 2:1 ratio) is a robust epidemiological pattern. The additional

information from ICD-11 that girls tend to have earlier symptom onset when GAD begins in childhood or adolescence adds a developmental layer to this disparity. This suggests that gender-related factors, which could encompass biological predispositions, psychological coping styles, emotional expression patterns, or socio-cultural influences (e.g., gender roles, exposure to stressors), may contribute to both the higher prevalence and earlier manifestation of GAD in females. This calls for gender-sensitive approaches in both research and clinical practice to better understand and address these disparities.

Typical Course/Progression

The course of GAD is generally characterized by chronicity and fluctuation. The DSM-5-TR states that GAD symptoms tend to be chronic and wax and wane across the life span, fluctuating between syndromal and subsyndromal forms of the disorder. It also observes that the course is more persistent in lower-income countries, but impairment tends to be higher in high-income countries.¹ ICD-11 similarly notes that symptom severity often fluctuates between threshold and subthreshold forms of the disorder, and full remission of symptoms is uncommon.¹

Both manuals emphasize the chronic, fluctuating nature of GAD, with symptoms waxing and waning and full remission being uncommon. This is a critical prognostic indicator, distinguishing GAD from more episodic disorders. The DSM-5-TR adds a nuanced socio-economic observation: while the underlying course may be *more persistent* in lower-income countries, the *impairment* tends to be higher in high-income countries. This suggests that while underlying chronicity may be universal, the *impact* of the disorder is significantly influenced by environmental factors. High-income countries, despite potentially better access to care, might present higher functional demands or different societal expectations that exacerbate perceived impairment. This calls for a broader public health perspective that considers socio-economic determinants of health in understanding and managing GAD.

Recurrence Rates

Neither the DSM-5-TR nor the ICD-11 CDDR explicitly provide specific recurrence rates for GAD.¹ The descriptions of its "chronic and wax and wane" course¹ and "uncommon" full remission¹ imply a persistent rather than an episodic-recurrent pattern. The absence of explicit recurrence rates, coupled with the description of GAD as a "chronic" disorder with symptoms that "wax and wane" and with "very low" rates of full remission, suggests that GAD is often a persistent condition rather than one characterized by discrete episodes of full remission followed by recurrence. This understanding shifts the focus of long-term management from preventing "recurrence" to sustaining "remission" or managing chronic symptoms, emphasizing ongoing support and symptom modulation rather than episodic

treatment.

Prognosis with Treatment

The prognosis for full symptom remission in GAD is generally guarded. Both the DSM-5-TR and ICD-11 consistently state that rates of full remission are "very low" or "uncommon".¹ This implies that while treatment can significantly reduce symptoms and improve functioning, complete eradication of symptoms is rare. This shapes realistic treatment goals for both clinicians and patients, emphasizing symptom management, functional improvement, and improved quality of life rather than a complete "cure."

Prognostic Indicators (Good/Poor)

A significant prognostic indicator mentioned by both manuals is the age of symptom onset. The DSM-5-TR notes that earlier onset of GAD symptoms is associated with more comorbidity and impairment.¹ Similarly, ICD-11 states that earlier onset of symptoms is associated with greater impairment of functioning and presence of co-occurring mental disorders.¹ The DSM-5-TR also adds that younger adults tend to experience greater severity of symptoms than older adults.¹

The consistent identification of earlier symptom onset as a poor prognostic indicator across both systems is a crucial clinical takeaway. This suggests that GAD, when manifesting earlier in life, may be more complex and potentially more resistant to treatment. The observation that younger adults experience greater symptom severity than older adults is also important. This emphasizes the need for early and potentially more intensive intervention for GAD, particularly when it manifests in childhood or adolescence, as these cases may be more complex and resistant to treatment. The lower severity in older adults might suggest an adaptive process or a "burnout" of symptoms over a very long course.

Specific typical recovery timeframes or early warning signs of relapse are not explicitly detailed in the provided materials from either DSM-5-TR or ICD-11 CDDR.

Etiological and Risk Factors

Genetic Factors

Genetic predisposition plays a role in the development of GAD. The DSM-5-TR indicates that approximately one-third of the risk of experiencing GAD is genetic.¹ Furthermore, these genetic factors overlap with the risk of negative affectivity (neuroticism) and are shared with

other anxiety and mood disorders, particularly major depressive disorder.¹ While ICD-11 CDDR does not explicitly detail GAD-specific genetic factors, it notes that obsessive-compulsive and related disorders (a broader grouping) frequently co-occur, which "may be related in part to shared genetic factors".¹

The DSM-5-TR's statement that "one-third of the risk... is genetic" and that these genetic factors "overlap with... negative affectivity (neuroticism) and are shared with other anxiety and mood disorders, particularly major depressive disorder" is a profound etiological understanding. This indicates a transdiagnostic genetic vulnerability, where common genetic predispositions contribute to a spectrum of internalizing disorders. This understanding moves beyond a disorder-specific genetic model to one of shared underlying biological predispositions, which helps explain the high rates of comorbidity between GAD, other anxiety disorders, and depressive disorders. It also suggests that interventions targeting these shared vulnerabilities might be broadly effective.

Neurobiological Factors

While specific neurobiological mechanisms are not extensively detailed, the DSM-5-TR identifies several temperamental factors with neurobiological underpinnings. These include behavioral inhibition, negative affectivity (neuroticism), harm avoidance, reward dependence, and attentional bias to threat, all of which have been associated with GAD.¹ ICD-11 CDDR does not explicitly detail specific neurobiological factors for GAD.

The mention of "attentional bias to threat" in the DSM-5-TR, while not detailing specific brain regions or neurotransmitters, points to a cognitive processing style that is likely rooted in neurobiological circuitry. This bias means individuals with GAD are predisposed to selectively attend to and interpret ambiguous information as threatening. This suggests that GAD is not merely a psychological state but involves altered cognitive processing, potentially reflecting underlying neural network dysregulation. This understanding can inform cognitive-behavioral therapies that aim to modify these attentional biases.

Psychological Factors

Temperamental factors are considered significant psychological predispositions to GAD. The DSM-5-TR lists behavioral inhibition, negative affectivity (neuroticism), harm avoidance, and reward dependence as temperamental factors associated with GAD.¹ ICD-11 CDDR does not explicitly detail specific psychological factors for GAD.

The DSM-5-TR's emphasis on temperamental factors like "negative affectivity" and "harm avoidance" highlights stable individual differences that increase vulnerability to GAD. These are not just symptoms but underlying personality traits that predispose an individual to experience negative emotions and perceive situations as threatening. This suggests that GAD often develops in individuals with a pre-existing anxious temperament, which can be identified

early in life. Psychological interventions might benefit from addressing these core temperamental styles, rather than solely focusing on symptom reduction.

Environmental / Social Factors

Environmental and social factors contribute significantly to the risk and manifestation of GAD. The DSM-5-TR notes that childhood adversities and certain parenting practices, such as overprotection, overcontrol, and reinforcement of avoidance, have been associated with GAD.¹ Furthermore, in the United States, a higher prevalence of GAD is associated with exposure to racism and ethnic discrimination, and for some ethnoracial groups, with being born in the United States.¹ ICD-11 highlights that realistic worries may be misjudged as excessive without appropriate contextual information, providing the example of migrant workers who may worry greatly about being deported due to actual threats from their employer.¹

Both manuals acknowledge the role of environmental factors. The DSM-5-TR's explicit mention of "racism and ethnic discrimination" as factors associated with higher prevalence in the US is a critical understanding, linking systemic social stressors to mental health outcomes. ICD-11's example of "migrant workers worrying about deportation" emphasizes that what might appear as "excessive worry" from one perspective can be a realistic and adaptive response to a threatening environment. This underscores that GAD is not solely an individual pathology but can be profoundly influenced by broader societal and environmental contexts. Clinical assessment must therefore consider the individual's lived experiences, including exposure to discrimination or significant life stressors, to accurately interpret symptoms and avoid pathologizing normal reactions to adverse circumstances.

Cultural / Religious Factors

Cultural and religious factors profoundly shape the presentation and interpretation of GAD. The DSM-5-TR states that there is considerable cultural variation in the expression of GAD, with somatic symptoms potentially predominating in some contexts and cognitive symptoms in others. The topic of worry itself can be culturally specific.¹ ICD-11 expands on this, noting that for many cultural groups, somatic complaints rather than excessive worry may predominate. Symptoms of fear and anxiety may be described primarily in terms of external forces (e.g., witchcraft, sorcery, malign magic or envy), rather than as an internal experience or psychological state.¹ Worry content may also vary by cultural group, relating to topics salient in the milieu, such as the spiritual status of deceased relatives in the afterlife, or personal achievement in more individualistic cultures.¹

The consistent emphasis on cultural variations in symptom expression (somatic versus cognitive) and the external attribution of anxiety is a profound cultural understanding. It highlights that the subjective experience and communication of anxiety are deeply embedded in cultural frameworks. Worry content can also be culturally or religiously specific. Clinicians

must adopt a culturally sensitive approach, actively inquiring about the patient's own understanding of their symptoms and their cultural context. Imposing a Western-centric view of "psychological distress" onto a somatically expressed or externally attributed experience can lead to misdiagnosis, lack of patient engagement, and ineffective treatment.

Developmental History

The developmental trajectory of anxiety is relevant to GAD. The DSM-5-TR notes that many individuals with GAD report feeling anxious and nervous throughout their lives, suggesting that symptoms of excessive worry and anxiety may occur early in life, manifesting as an anxious temperament.¹ It also states that earlier onset of GAD symptoms is associated with more comorbidity and impairment.¹ ICD-11 similarly indicates that GAD is uncommon in children younger than 5 years due to less developed cognitive abilities that support the capacity for worry, which is a core feature of the disorder. It reiterates that earlier onset of symptoms is associated with greater impairment of functioning and presence of co-occurring mental disorders.¹

The idea that GAD symptoms may manifest early in life as an "anxious temperament" is a key developmental understanding, suggesting a predisposition rather than a sudden onset. The ICD-11's specific point about GAD being uncommon before age 5 due to underdeveloped cognitive abilities for worry provides a crucial developmental milestone for the emergence of the disorder's core cognitive feature. This highlights the importance of early developmental screening for anxious temperament and understanding that the *form* of anxiety may change with cognitive development. Early intervention efforts could target these temperamental vulnerabilities before full GAD criteria are met.

Family History

While not explicitly detailed as "family history" in the provided snippets, the genetic contribution to GAD strongly implies a familial pattern. The DSM-5-TR states that one-third of the risk of experiencing GAD is genetic, and these genetic factors overlap with the risk of negative affectivity (neuroticism) and are shared with other anxiety and mood disorders, particularly major depressive disorder.¹ ICD-11 mentions shared genetic factors for obsessive-compulsive and related disorders, which are broadly related to anxiety.¹

The significant genetic contribution and its overlap with other anxiety and mood disorders strongly suggest a familial aggregation of GAD and related internalizing disorders. This indicates a shared underlying biological predisposition. Clinicians should routinely inquire about family history of anxiety, depression, and related disorders, as it serves as a significant risk factor for GAD and can inform a broader understanding of the patient's vulnerability.

Assessment Methods

Structured Interviews, Self-Report Measures, Clinician-Rated Scales, Psychometric Tools, Observation Methods

Neither the DSM-5-TR nor the ICD-11 CDDR explicitly list or describe specific assessment tools or methods for GAD, such as structured interviews, self-report measures, clinician-rated scales, psychometric tools, or observation methods.¹ Their primary function is to provide diagnostic criteria and clinical descriptions, not to serve as comprehensive guides for clinical assessment.

The absence of specific assessment tools in these authoritative diagnostic manuals is a notable gap from a practical clinical perspective. This is inherent to their purpose as classification systems. They define *what* constitutes a disorder, but not *how* to systematically assess it beyond general clinical interview. This highlights that clinicians must rely on external, validated resources, such as specialized clinical guidelines or psychometric handbooks, for appropriate assessment tools and methods.

Lab / Neuroimaging Considerations

Laboratory and neuroimaging considerations in GAD primarily serve an exclusionary role. Both the DSM-5-TR and ICD-11 emphasize the necessity of ruling out underlying medical conditions or substance effects as primary causes of anxiety symptoms.¹ For instance, DSM-5-TR explicitly mentions hyperthyroidism and pheochromocytoma as medical conditions to consider.¹ This implicitly necessitates a medical workup, including relevant lab tests, to exclude physiological causes of anxiety symptoms. The lack of *positive* diagnostic markers for GAD itself means that lab and neuroimaging studies primarily serve an exclusionary role, ensuring that anxiety symptoms are not masking an untreated physical illness. This is a crucial practical step in the diagnostic process for GAD, preventing misdiagnosis and ensuring appropriate treatment.

Treatment and Management Strategies

The provided diagnostic manuals, DSM-5-TR and ICD-11 CDDR, are primarily classification systems and do not offer detailed information on specific treatment modalities for Generalized Anxiety Disorder. This includes first-line pharmacological treatments, alternative pharmacological options, medication side effects, medication monitoring requirements,

recommended psychotherapy modalities, core therapeutic goals, therapist role/approach, or maintenance treatment options.¹

The consistent absence of information on specific treatments, their side effects, monitoring, or maintenance options across both diagnostic manuals clearly delineates their scope. These documents are designed for classification and diagnosis, not for clinical management protocols. This highlights the necessity for clinicians to consult specialized treatment guidelines, clinical practice recommendations, and pharmacotherapy resources for evidence-based management of GAD. The information provided in these manuals is foundational for *what* to treat, but not *how* to treat.

Common Challenges in Treatment

While not extensively detailed, some challenges in GAD treatment can be inferred from the provided information. The DSM-5-TR notes that high levels of anxiety have been associated with a greater likelihood of treatment nonresponse.¹ Additionally, the presence of comorbidity can complicate treatment. For instance, individuals with comorbid agoraphobia and major depressive disorder tend to have a more treatment-resistant course of agoraphobia, which implies that comorbidity can generally complicate the treatment of anxiety disorders.¹ ICD-11 CDDR does not explicitly detail specific challenges in GAD treatment.¹

Information regarding patient education recommendations, family psychoeducation, sleep and nutrition considerations, exercise and movement, mindfulness/spiritual practices, community or social support needs, and routine and structure guidance is not explicitly provided within the scope of these diagnostic manuals.¹

Special Population Considerations

Children & Adolescents

GAD is a common anxiety disorder in late childhood and adolescence, with its occurrence increasing as cognitive abilities that support worry develop. It is uncommon in children younger than 5 years due to less developed cognitive abilities for worry.¹ In children and adolescents, worries often concern the quality of their performance or competence at school or in sporting events, even when their performance is not being evaluated by others. They may have excessive concerns about punctuality or catastrophic events.¹ Children with GAD may be overly conforming, perfectionistic, unsure of themselves, and tend to redo tasks due to excessive dissatisfaction with less-than-perfect performance. They may also be overzealous in seeking reassurance and approval, asking repetitive questions, and showing distress when

faced with uncertainty.¹ Somatic symptoms, particularly those related to sympathetic autonomic overactivity (e.g., headaches, abdominal pain, gastrointestinal distress), and sleep disturbances are common in children with GAD.¹ Worry content shifts with age: younger children tend to worry about safety and health, while adolescents worry more about performance, perfectionism, and meeting expectations.¹ Adolescents with GAD may exhibit increased irritability and are at higher risk for co-occurring depressive symptoms.¹

Older Adults

In older adults, the content of worry often shifts to age-appropriate concerns. The DSM-5-TR notes that the advent of chronic physical disease can be a potent issue for excessive worry in the elderly. For the frail elderly, worries about safety, especially about falling, may limit activities.¹ The 12-month prevalence of GAD in older adults (including those age 75 years and older) ranges from 2.8% to 3.1% in the United States, Israel, and European countries.¹ Information regarding GAD in pregnancy & postpartum populations or specific LGBTQIA+ considerations is not explicitly provided in the supplied documents.

Substance Use Complications

Substance use can have a complex relationship with GAD. Both DSM-5-TR and ICD-11 explicitly state that GAD symptoms are **not** attributable to the physiological effects of a substance or medication on the central nervous system, including withdrawal effects.¹ If anxiety symptoms are caused by substance use, they would be classified as a substance/medication-induced anxiety disorder.¹

However, GAD can co-occur with substance use disorders. The DSM-5-TR notes that while comorbidity with substance use disorders is less common than with other anxiety and unipolar depressive disorders, it can still occur.¹ ICD-11 states that men with GAD are more likely to experience co-occurring disorders due to substance use.¹ The DSM-5-TR also highlights that persistent insomnia, a common symptom of GAD, is a risk factor for substance use disorders. Individuals with insomnia may misuse medications or alcohol for sleep, anxiolytics for tension, and caffeine or stimulants for daytime fatigue, potentially leading to a substance use disorder.¹ This indicates that while substance use does not *cause* GAD, it can *co-occur* and complicate its presentation and management.

Suicidality / Risk Management

Generalized Anxiety Disorder is associated with increased suicidal thoughts and behavior, even after accounting for co-occurring disorders and stressful life events.¹ Psychological

autopsy studies indicate that GAD is the most frequently diagnosed anxiety disorder in suicides.¹ Both subthreshold and threshold GAD occurring in the past year may be linked to suicidal thoughts.¹ For risk management, the DSM-5-TR highlights that high levels of anxiety have been associated with higher suicide risk, longer duration of illness, and a greater likelihood of treatment nonresponse. Therefore, accurately specifying the presence and severity levels of anxious distress is clinically useful for treatment planning and monitoring of response to treatment.¹

Specific information on case summaries, presenting problems, interventions, outcomes, direct text quotes, page numbers, or editor/author notes is not provided in the research materials.

Conclusion

Generalized Anxiety Disorder is a chronic and pervasive condition characterized by excessive worry and a range of cognitive, emotional, behavioral, and somatic symptoms that lead to significant distress and functional impairment. Both the DSM-5-TR and ICD-11 CDDR offer robust frameworks for its diagnosis, emphasizing the exclusion of medical conditions and substance-induced effects, and careful differentiation from other mental disorders with overlapping symptoms.

While the manuals largely align in their core conceptualization of GAD, subtle differences exist, particularly in the precision of duration requirements and symptom quantification. The DSM-5-TR leans towards more stringent, quantifiable criteria, which supports research comparability, whereas ICD-11 prioritizes clinical utility and flexibility, acknowledging cultural variations in symptom expression. These differences highlight the distinct philosophical underpinnings of each system and carry implications for international diagnostic consistency and the generalizability of research findings.

The understanding of GAD has evolved to recognize its strong genetic component, often shared with other anxiety and mood disorders, pointing to a transdiagnostic vulnerability. Environmental factors, including childhood adversities and parenting styles, as well as broader societal stressors like racism and discrimination, play a significant role in its development and prevalence. The manifestation of GAD is also deeply influenced by cultural context, with somatic complaints often predominating over cognitive expressions in many non-Western populations, necessitating a culturally informed diagnostic approach.

The course of GAD is typically chronic, with symptoms waxing and waning, and full remission being uncommon. Earlier age of onset is consistently identified as a poor prognostic indicator, associated with greater impairment and comorbidity. While the diagnostic manuals provide comprehensive criteria, they do not extend to detailed treatment guidelines, assessment tools, or specific recovery timeframes, underscoring the need for clinicians to consult specialized resources for evidence-based management. The association of GAD with increased suicidality, even independently of comorbidities, further emphasizes the critical importance of accurate diagnosis and comprehensive treatment planning that addresses the

severity of anxiety.

Works cited

1. ICD-11.pdf